Article
Medicine, General & Internal
Lu Gao, Ming-qiang Ren, Zu-guo Tian, Zhi-yuan Peng, Genghui Shi, Zhong Yuan
Summary: Chronic myelogenous leukemia patients with thrombocytosis and complex chromosomal translocation are extremely rare, and treatment with imatinib may be the preferred option. Performing BCR/ABL fusion gene examination can be an effective strategy to avoid misdiagnosis in patients with thrombocytosis.
Article
Oncology
Ismail Siti Mariam, Ramli Norhidayah, Abu Bakar Zulaikha, Mohd Yunus Nazihah, Hassan Rosline, Ghazali Anis Kausar, Sulong Sarina, Husin Azlan, Ravindran Ankathil
Summary: This study reports the type, frequency, and prognostic impact of additional chromosome abnormalities (ACAs) in Malaysian chronic myeloid leukemia (CML) patients undergoing treatment with tyrosine kinase inhibitors (TKIs). The patients with ACAs were stratified into different groups, and it was found that the prognostic outcomes varied significantly among these groups. This study suggests that stratification based on individual ACAs can help predict prognosis and guide treatment decisions for CML patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Zachary D. Epstein-Peterson, Andriy Derkach, Susan Geyer, Krzysztof Mrozek, Jessica Kohlschmidt, Jae H. Park, Sridevi Rajeeve, Eytan M. Stein, Yanming Zhang, Harry Iland, Lynda J. Campbell, Richard A. Larson, Xavier Poire, Bayard L. Powell, Wendy Stock, Richard M. Stone, Martin S. Tallman
Summary: In this study, a pooled analysis of ATO-treated APL patients revealed that patients with a complex karyotype had inferior event-free survival, while the presence of additional cytogenetic abnormalities did not significantly impact survival. These findings emphasize the importance of conducting full karyotypic analysis in all APL patients and highlight the need for novel treatment strategies to overcome the adverse effects of APL with a complex karyotype.
Article
Hematology
Richard E. Clark, Jane F. Apperley, Mhairi Copland, Silvia Cicconi
Summary: In patients with chronic-phase CML, the presence of additional cytogenetic abnormalities (ACAs) beyond the standard Philadelphia translocation is associated with a higher risk of disease progression, leading to poorer progression-free survival (PFS) and freedom from progression (FFP). The study found that certain ACAs are predictive of disease progression independent of traditional risk scores like Sokal or ELTS.
Review
Oncology
Khalil Saleh, Alexis Fernandez, Florence Pasquier
Summary: The outcome of patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) has dramatically improved in the past 20 years with the introduction of tyrosine kinase inhibitors and monoclonal antibodies. These treatments have shown great efficacy in young and fit patients, leading to questioning the reliance on chemotherapy and stem cell transplantation. They can also be safely used in elderly patients, who make up the majority of Ph+ ALL patients. This review focuses on the recent changes in the management of Ph+ ALL patients and the development of new therapeutic strategies.
Review
Oncology
Sana Ansari, Malkhey Verma
Summary: Chronic myeloid leukemia (CML) is a blood cancer that affects hematopoietic stem cells and is characterized by the presence of the Philadelphia chromosome (Ph+). The Ph+ chromosome expresses a protein with elevated tyrosine kinase activity, which is considered tumorigenic. Imatinib, a potent tyrosine kinase inhibitor, is the first line of therapy for CML. Other TKIs are used in cases of imatinib failure/resistance. The development of TKIs has improved CML treatment and overall survival.
Review
Medicine, General & Internal
Robin Foa, Sabina Chiaretti
Summary: Current frontline therapy for Ph-positive acute lymphoblastic leukemia, which includes tyrosine kinase inhibitors, glucocorticoids, and blinatumomab, has significantly improved survival and achieved high-level clearance of measurable tumor cells.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Muhammad Naveed, Noor ul Ain, Tariq Aziz, Khushbakht Javed, Muhammad Aqib Shabbir, Metab Alharbi, Abdulrahman Alsahammari, Abdullah F. Alasmari
Summary: BCR-ABL1 is a fusion protein that is used as a clinical biomarker primarily for chronic myeloid leukemia (CML). This study explores the use of gamma-tocotrienol as a BCR-ABL1 inhibitor and utilizes deep learning artificial intelligence (AI) drug design to develop new drug compounds. The research shows that the AI-designed gamma-tocotrienol is effective and more hepatoprotective than the currently provided medications. However, further in vivo testing is needed for verification.
Article
Oncology
Koji Sasaki, Hagop M. Kantarjian, Nicholas J. Short, Bachar Samra, Joseph D. Khoury, Rashmi Kanagal Shamanna, Marina Konopleva, Nitin Jain, Courtney D. DiNardo, Rita Khouri, Guillermo Garcia-Manero, Tapan M. Kadia, William G. Wierda, Issa F. Khouri, Partow Kebriaei, Rohtesh S. Mehta, Richard E. Champlin, Rebecca Garris, Cora Marie Cheung, Naval Daver, Philip A. Thompson, Musa Yilmaz, Farhad Ravandi, Elias Jabbour
Summary: In patients with Ph-positive ALL, ponatinib is superior to other types of TKIs in inducing and maintaining a CMR, thus preventing disease progression. ASCT does not improve outcome once a 3-month CMR is achieved.
Article
Genetics & Heredity
Ahmed Maseh Haidary, Zeeshan Ansar Ahmed, Jamshid Abdul-Ghafar, Soma Rahmani, Sarah Noor, Farahnaz Erfani, Maryam Ahmad, Naeem Lakanwall, Haider Ali Malakzai, Abdul Sami Ibrahimkhil, Esmatullah Esmat, Mujtaba Haidari, Nimattullah Yousufzai, Samuel Sharif, Abdul Hadi Saqib
Summary: 5q deletions are rare in CML, with reported cases either linked to tyrosine kinase inhibitor therapy or post allogeneic stem cell transplantation. This case represents the first reported instance of Ph positive CML accompanied by a 5q deletion.
MOLECULAR CYTOGENETICS
(2021)
Article
Pharmacology & Pharmacy
Francois Pierre Combes, Ying Fei Li, Matthias Hoch, Sebastien Lorenzo, Yu-Yun Ho, Sherwin K. B. Sy
Summary: Asciminib has potent activity against the T315I mutation in chronic myeloid leukemia patients. A longitudinal pharmacokinetic/pharmacodynamic model was developed to characterize the exposure-efficacy relationship of Asciminib. The model demonstrated the appropriateness of different doses for patients with or without the T315I mutation.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Oncology
Chunmou Li, Luping Wen, Junchao Dong, Lindi Li, Junbin Huang, Jing Yang, Tianqi Liang, Tianwen Li, Zhigang Xia, Chun Chen
Summary: Incidence rates of CML and Ph+ ALL are lower but more aggressive in children than in adults. TKI treatment has significantly improved the prognosis for children, but off-target effects and drug tolerance may occur. Changes in cellular metabolism may contribute to drug resistance and side effects during TKI treatment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Wendy Stock, Giovanni Martinelli, Matthias Stelljes, Daniel J. DeAngelo, Nicola Goekbuget, Anjali S. Advani, Susan O'Brien, Michaela Liedtke, Akil A. Merchant, Ryan D. Cassaday, Tao Wang, Hui Zhang, Erik Vandendries, Elias Jabbour, David Marks, Hagop M. Kantarjian
Summary: The study demonstrated that InO was more effective than standard intensive chemotherapy for patients with R/R Ph+ ALL, showing higher rates of complete remission and minimal residual disease negativity, as well as improved hematopoietic stem cell transplantation rates. However, there was no significant benefit in overall survival, and the probability of being event-free at 12 months was higher with InO treatment.
Review
Hematology
Brunangelo Falini
Summary: The importance and relevance of NPM1 mutations in AML, including their involvement in chromatin-level regulation and gene expression, as well as their implications for classification and potential targeted therapies.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Bani Bandana Ganguly, Shouvik Mandal, Debasis Banerjee, Nitin N. Kadam
Summary: This study describes the cytogenetic remission, relapse, response to different TKIs, and behavior of ACAs in a case of CML. The results indicate the complexity of ACAs and Ph+ clones, which need frequent monitoring and management with changes in TKI and technologies.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2022)
